We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.
News & insights
News: 07 JANUARY 2020
A&O has marked the end of Q4 2019 with a stellar performance in the M&A league tables; the result of advising on a number of complex, high-value transactions in a wide range of sectors and markets, around our global network in 2019.Read more
Publications: 29 NOVEMBER 2019
As more countries liberalise their cannabis policies, there has been a rapid increase in the number of registered IP rights as competitors seek to establish their places in the market.Read more
Publications: 04 OCTOBER 2019
A&O has marked the end of Q3 2019 with an outstanding performance in the M&A league tables; the result of advising on a number of complex, high-value transactions in a wide range of sectors and markets, around our global network in 2019.Read more
Publications: 28 AUGUST 2019
On 8 August 2019, the National Institute for Health and Care Excellence (NICE)1 published a draft guideline on prescribing cannabis-based medicinal products (the Draft Guideline) for consultation.2Read more